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Abstract
Introduction
Finding new markers to assess prognosis of melanoma without the necessity to perform a
surgical interventions is an important goal in melanoma research. The current study aimed
to assess the correlation of clinical course and prognosis of primary and metastatic mela-
noma with expression of VEGF family and their receptors.
Methods
A ngTMA block was made from the randomly selected paraffin tissue blocks of the patients
with melanocytic nevi, primary and metastatic melanoma. Then sections cut from ngTMA-
block were immunohistochemically stained with proper antibodies. Expression of these
proteins was investigated using automated image analysis and compared among the study
groups.
Results
We analyzed the tissue of 238 patients with following diagnoses: 101 (42.4%) with a diagno-
sis of nevus, 86 (36.1%) Malignant melanoma and 51 (21.4%) metastasis. Median follow-up
time for the malignant lesions was 5.71 years. Among the tested antigen, VEGF-C (p =
0.016), VEGF-R2 (p<0.001) and VEGF-R3 (p = 0.002) were significantly higher expressed
in the metastatic tissues. When these scores were assessed in multiple regression models,
the only independent factor linked to patient’s diagnosis was VEGF-R2 (p<0.001). In addi-
tion, groups of highly correlated variables (VEGF-C and VEGF-R3, VEGF-A and VEGF-R1)
were found to form separate sub-clusters. On the other side, high values of VEGF-C were
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associated with both overall and disease-free survival with a statically significant HR of 2.76
(95% CI: 1.27, 5.98; p = 0.01) and 2.82 (95%CI: 1.62, 4.91; p<0.001), respectively.
Conclusions
This study shows that VEGF-C and VEGF-R2 might represent new prognostic marker in
MM. However, further prospective studies are warranted to test their real efficacy as a prog-
nostic marker.
Introduction
Malignant melanoma (MM) is a malignant tumor arising from an uncontrolled growth of
melanocytes, [1, 2] responsible for 90% of the deaths associated with cutaneous tumors. [1, 3,
4] The prognosis of patients with melanoma is tumor-stage dependent. The most important
prognostic marker is he Breslow-thickness followed by the presence of an ulceration, and the
presence of mitoses. Sentinel lymph node biopsy (SLNB) is a further procedure to acquire
some more prognostic informations. [5–7] However, this surgical procedure is costly and
might cause significant complications such as lymphocele (23%), wound infection (19%),
extremity swelling (17%), and seroma (15%). [8, 9] Thus, it is an important goal in melanoma
research, to find markers to assess the metastatic risk of disease without having to perform a
surgical intervention.
In tumorigenesis, the formation, differentiation and growth of blood vessels are absolute
necessary for the development, expansion, and spread of a tumors. [10, 11] Moreover, the vas-
cular network is also fundamental to allow the metastatic cascade, [12, 13] which requires the
transport of malignant cells through the blood and/or lymph vessels. [14] The expression of
some important angiogenic factors as the Vascular Endothelial Growth Factor (VEGF) sub-
types and their receptors (VEGF-Rs), is upregulated on vascular endothelial cells during
tumor angiogenesis and correlates with tumor growth rate, microvessel density, tumor prolif-
eration, tumor metastatic potential and finally poorer patient prognosis. This has been demon-
strated in different malignant tumours and in different organs [11, 14–16]: breast, [17] colon,
[18, 19] lung, [20, 21] thyroid, [22–24] gastric [25] squamous cell cancers, [26] mesotheliomas,
[27] neuroblastomas, [28] and sarcomas. [26]
However, the role of such angiogenic factors on the clinical follow up and disease-progno-
sis, inclusive patient-survival in MM remains unclear. [13] With this study for the first time,
we aimed to assess the correlation between the expression of various VEGF/receptors, and the
clinical course and prognosis of patients with primary and metastatic melanoma.
Material and methods
Study population and clinical data collection
The analyses have been performed on the paraffin tissue blocks from the archives of the Der-
matopathology Unit at the Department of Dermatology, Inselspital, Bern University Hospital,
Switzerland. (2003–2015) We randomly selected cases with following diagnosis: melanocytic
nevi (n = 120), primary melanoma (n = 134) and metastatic melanoma (n = 76). The blocks
with proper and enough tissue for the immunohistochemical staining (minimum of 4 mm
thickness) were included in the study. Furthermore, the patients without complete documents
and/or regular clinical follow-up were excluded. This study was conducted in accordance with
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the standards of the Ethical Committee of the Canton of Bern on human experimentation and
with the Helsinki Declaration of 1975, as revised in 1983.
We collected data of patients’ gender, age, tumor anatomical location, tumor type, Breslow
thickness, ulceration, sentinel lymph node status, presence of distant and/or locoregional
metastases. In the current study, local recurrences can represent either persistent disease due
to inadequate initial excision or true recurrence adjacent to the scar after adequate prior wide
local excision and usually have an in situ component, or they may represent satellite metasta-
ses. Locoregional recurrence of melanoma after initial resection was defined as recurrence at
the site of the primary lesion, regionally in the draining lymph node basin, or anywhere in
between. [29, 30] The spreading from the original (primary) tumor to distant organs or distant
lymph nodes is considered as distant metastases. [30, 31]
Next-generation Tissue Microarray (ngTMA)
As discussed before, [32] the last histological Haematoxylin and Eosin (H&E) slide of each
patient was retrieved. The H&E stained slides were scanned using panoramic Digital Slide
Scanner (3DHISTECH). Using the free digital slide viewer software, the digital slides were
evaluated and areas of interest for integration into the ngTMA were found. The annotation
(600 μm) was thereafter moved to the desired histological structures for incorporation into the
ngTMA. Then, a list of all cases with their corresponding annotations was created. The corre-
sponding paraffin tissue blocks for all annotated digital slides were retrieved and sorted in the
desired order for tissue microarraying. Next, the donor blocks were loaded up into the tissue
microarrayer. Then the tissue microarrayer started to drill holes of 0.6 mm in diameter in the
recipient block at the selected starting point. In the next step, using the punching tool, the
instrument punched holes into the tissue from the selected donor block at the exact annotated
and confirmed region. Cores (only one per patient) are then transferred from the donor to the
recipient block. [32] (S1 Fig).
Immunohistochemical staining
From the prepared ngTMA-block new sections were cut to perform immunohistochemical
stainings.
The automated staining was performed using the BOND-III fully automated IHC and ISH
stainer (Leica Biosystems) according to the manufacturer’s instructions. In brief, paraffin-
embedded tissue sections were first dewaxed and rehydrated, followed by epitope retrievel
(epitrope-retrieval solution 2; Leica). They were then incubated with following primary anti-
bodies for 15min: Anti-VEGF-A antibody (abcam), anti-VEGF-B antibody (R&D systems),
anti-VEGF-C antibody (biorbyt), anti-VEGF-D antibody (R&D systems), anti-VEGF-R1 anti-
body (biorbyt), anti-VEGF-R2 antibody (R&D systems) and anti-VEGF-R3 antibody (R&D
systems). This step was then followed by a post-primary-IgG-linker and a Poly-AP-IgG
reagent (Bond Polymer Refine Red Detection System, Leica). Sections were then developed in
Fast Red substrate chromogen (Leica) (S2 Fig, S1 Table).
Image analysis procedure
The stained slides were scanned by panoramic Digital Slide Scanner (3DHISTECH). The
scanned images were opened in the QuPath (Queen’s University Belfast) digital image analysis
system. Then the tissue cores were automatically detected using ngTMA dearrayer. After mod-
ifications of the individual selected cores, unsuitable cores for analysis, were marked as “Miss-
ing data” and excluded. To perform automatic quantification of immunohistochemistry red
stained tissue by measurement of optical density of red color—which is proportional to the
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expression extent of specific antigens, [33] Image J (NIH, Bethesda, MD, USA) macro runner
was applied in QuPath (Queen’s University Belfast) to run the proper ImageJ macro (https://
imagej.nih.gov/ij/docs/examples/stained-sections/index.html) based on extracting image
regions from each ngTMA. In order to validate the full-automated image analysis, all 2975
stained cores were also evaluated by an experienced staff using a semi-quantitative scale, as
followings: 0 = absent; 1 = very low expression; 2 = low expression; 3 = moderate expression;
4 = strong expression; 5 = very strong expression (Fig 1).
Statistical analysis
Data were presented as means with standard deviations (SD) or numbers with percentages for
continuous and categorical variables respectively. One-way MANOVA was used to analyse dif-
ferences in the distribution of the scores across groups of patients with a different diagnosis
(nevus, MM or metastasis). [34] Differences were computed along with their 95% confidence
intervals (CI) and p-values. In addition, in order to assess which factors were independent pre-
dictors for the diagnosis, all variables with a p-value <0.15 in MANOVA analysis were evalu-
ated for inclusion in multinomial logistic regression models with stepwise forward selection
algorithm.
The association between each pair of scores was also investigated by means of Pearson’s r
correlation coefficient. Groups of correlated scores were then analysed by using hierarchical
clustering with Pearson’s correlation as proximity measure and centroid linkage as partition-
ing criterion. [35] Clusters were displayed by using a tree diagram (dendrogram), where at
each node a two sub-branch of clustered group of variables are represented; the height of
nodes represents the distance between pair of clusters. In addition, principal component analy-
sis (PCA) was used as an alternative approach to show clustering among correlated variables.
[36] Differences between patients with MM and metastases across demographics and clinical
characteristics were tested by means of Pearson’s χ2 test or Mann-Whitney U test for categori-
cal and continuous variables respectively. For analysis purposes continuous variables were also
categorized by using clinically relevant cut-off points.
For each kind of diagnosis (MM or metastasis), one-way MANOVA was used to analyse
differences in the distribution of the scores across demographics and clinical characteristics.
All variables with a p-value <0.15 in MANOVA analysis were evaluated for inclusion in multi-
variate generalized linear models (GLM) with stepwise forward selection algorithm.
Overall and disease-free cumulative survival rates along with their 95% CI were computed
using Kaplan-Meier estimator. For the aims of this analysis, scores were also categorized in
low vs. high values based on significance of correlation with survival outcomes. [37] Optimal
cut-off values were defined as the points with the most significant split according to the log-
Fig 1. Semi-quantitative scale, as followings: (from left to right) 0 = absent; 1 = very low expression; 2 = low expression; 3 = moderate expression; 4 = strong
expression; 5 = very strong expression.
https://doi.org/10.1371/journal.pone.0207019.g001
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rank test, which was used to assess overall and disease-free survival differences between catego-
rized scores.
Scores with a p-value <0.15 in the univariate survival analysis were then evaluated for
inclusion in multiple Cox regression models with forward stepwise selection algorithm. The
relative risk of mortality was expressed in terms of hazard ratio (HR) along with its 95% CI
and p-value.
The Benjamini–Hochberg procedure was used to account for multiple comparisons in all
multivariate tests by taking a false discovery rate of 0.05. [38] The critical p-values derived
from the procedure were reported as reference value to determine statistically significant find-
ings. For the purpose of validating the relationship between automated and non-automated
image analysis results, Pearson normalized correlation coefficient was applied. Analyses were
carried out with SPSS software v.20.0 (IBM Corp, Armonk, NY).
Results
Complete data on study scores were obtained for 238 subjects: 101 (42.4%) melanocytic nevus,
86 (36.1%) MM and 51 (21.4%) metastasis. The median follow-up time for the malignant
lesions was 5.71 years. Pearson normalized correlation coefficient showed significant strong
positive correlation between automated score and semi-quantitative evaluation (non-auto-
mated score). (p<0.001, r = 0.802)
Scores statistics, overall and by patient’s diagnosis, are shown in Table 1 (Fig 2). Overall
there was a significant difference of the scores across diagnoses (p<0.001). More specifically
the only scores significantly associated with patient’s diagnosis, after accounting for multiple
comparisons, were VEGF-C (p = 0.016), VEGF-R2 (p<0.001) and VEGF-R3 (p = 0.002). For
all these scores, only the difference between nevus and metastasis was statistically significant
after accounting for multiple comparisons. When these scores were included in multinomial
logistic regression models, the only independent factor linked to patient’s diagnosis was
VEGF-R2 (p<0.001).
Then we explored the associations among automated scores. Overall there was a high corre-
lation between them, ranging from a minimum of r = 0.32 for VEGF-R1 and VEGF-R2 to a
maximum of r = 0.88 for VEGF-C and VEGF-R3 (S3 Table). Groups of correlated scores were
also analysed using hierarchical clustering. Looking at the dendrogram (Fig 3), proceeding
from right to left, it is possible to observe two large separated clusters of scores. The first one
comprises VEGF-C, VEGF-R2 and VEGF-R3, the same variables significantly associated to
patient’s diagnosis in MANOVA analysis, while on the other side we found the remaining vari-
ables. Going deeper down the tree, we find groups of highly correlated variables (VEGF-C and
VEGF-R3, VEGF-A and VEGF-R1) forming separate sub-clusters. VEGF-D is only moder-
ately correlated to VEGF-B. These two variables are quite distant in the graph to all the other
scores. These findings were also confirmed by adopting principal component analysis (PCA)
as an alternative approach (S3 Fig).
Demographics and clinical characteristics of patients with a specific diagnosis of MM or
metastasis are shown in Table 2. Overall 60% of patients were males with a mean age of
62.3 ± 15.8 (mean ± SD) years and without any significant differences between the two groups.
47.0% of patients had a superficial spreading MM and 29.1% a nodular MM, with a significant
different distribution between groups. 41.4% of subjects had a primary tumor located at the
trunk, while 36.8% at upper or lower extremities. Ulceration was detected in 25.2% of patients
with a significantly higher prevalence in the metastasis group. The average Breslow’s thickness
was 2.3 ± 2.7 mm and it was higher in the metastasis compared to the melanoma group (4.2 vs.
1.4, p<0.001). A positive sentinel lymph node was found in 25.3% of the patients.
Correlation of Vascular Endothelial Growth Factor with melanoma progression
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The distribution of study scores across demographics and clinical characteristics of patients
with a diagnosis of MM is reported in S3 Table. Factors with a p-value<0.15 in MANOVA
analysis and evaluated for inclusion in multivariate GLM were: tumor type, Breslow’s thick-
ness and sentinel lymph node findings. The final selected factors were tumor type and Bre-
slow’s thickness (Table 3). More specifically, VEGF-C and VEGF-R3 values significantly
decreased when superficial spreading MM and other diagnosis were compared with nodular
MM. On the other hand, VEGF-A, VEGF-B, VEGF-C, VEGF-R2 and VEGF-R3 values
increased when intermediate Breslow’s thickness is compared to the thin one. The same did
not hold for thick tumor type, where score values were not significantly different compared to
thin Breslow’s group.
S4 Table presents the association between study scores and demographics and clinical char-
acteristics of patients with metastasis. Factors with a p-value <0.15 in MANOVA analysis
were: sex, age and primary tumor location, which was the only factor retained in the multivari-
ate analysis (Table 3). Looking at the specific effect of single scores across different tumor loca-
tions, VEGF-A, VEGF-B, VEGF-C, VEGF-D and VEGF-R2 values were significantly higher
for lower extremities tumors compared to head and neck localisation. The value of the scores
in other locations was not significantly different, apart from VEGF-D that was also signifi-
cantly higher for the trunk.
Table 1. Scores statistics, overall and by patient’s diagnosis.
Mean, SD Difference (95% CI) P�, Cr. P��
VEGF-A Nevus 1.26, 0.64 Ref. 0.868, 0.050
MM 1.31, 1.31 0.05 (-0.23, 0.33) 0.723, 0.039
Metastasis 1.22, 0.86 -0.04 (-0.37, 0.29) 0.821, 0.043
VEGF-B Nevus 1.82, 0.93 Ref. 0.841, 0.043
MM 1.83, 1.43 0.004 (-0.34, 0.35) 0.980, 0.050
Metastasis 1.94, 1.22 0.11 (-0.29, 0.52) 0.583, 0.032
VEGF-C Nevus 4.91, 2.76 Ref. 0.016, 0.021
MM 5.73, 4.83 0.82 (-0.33, 1.97) 0.160, 0.021
Metastasis 6.87, 4.36 1.96 (0.62, 3.30) 0.004, 0.011
VEGF-D Nevus 3.91, 2.28 Ref. 0.697, 0.036
MM 4.24, 3.17 0.33 (-0.43, 1.09) 0.396, 0.029
Metastasis 4.08, 2.31 0.17 (-0.73, 1.06) 0.715, 0.036
VEGF-R1 Nevus 0.64, 0.35 Ref. 0.661, 0.029
MM 0.73, 1.08 0.10 (-0.12, 0.31) 0.377, 0.025
Metastasis 0.66, 0.58 0.02 (-0.23, 0.27) 0.882, 0.046
VEGF-R2 Nevus 10.75, 4.90 Ref. <0.001, 0.007
MM 12.84, 6.31 2.09 (0.39, 3.78) 0.016, 0.014
Metastasis 15.10, 6.80 4.35 (2.36, 6.33) <0.001, 0.004
VEGF-R3 Nevus 8.17, 4.17 Ref. 0.002, 0.014
MM 9.35, 6.64 1.18 (-0.45, 2.81) 0.156, 0.018
Metastasis 11.59, 6.31 3.42 (1.51, 5.33) 0.001, 0.007
CI: confidence interval, MM: malignant melanoma, P: p-value, SD: standard deviation
� P-values in italics are single p-values from one-way MANOVA analysis. Other p-values test the differences against a reference category for each score. The overall
difference of the scores across different diagnoses is significant at p<0.001.
�� Benjamini–Hochberg critical values for multiple comparisons with a false discovery rate of 0.05. A first set of tests was performed on the overall difference for each
score; then a second sub-set of tests was done on the specific differences within each score. Results must be considered statistically significant (boldfaced) only when
their p-values are lower than the corresponding critical values (Cr. P).
https://doi.org/10.1371/journal.pone.0207019.t001
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Overall and disease-free patients’ survival after a diagnosis of MM or metastasis was then
analysed until 15 years of follow-up. The overall cumulative survival at 5, 10 and 15 years was
83.2% (95% CI: 76.5, 89.9), 73.1% (63.1, 83.1) and 67.5% (53.4, 81.6) respectively. On the other
hand, the disease free survival for the same years was of 63.6% (55.0, 72.2), 55.0% (44.6, 65.4)
and 50.0% (36.7, 63.3).
Univariate analysis of the association between optimal categorized scores and overall and
disease-free patients’ survival revealed that VEGF-C, VEGF-R1, VEGF-R2 and VEGF-R3 were
possible factors associated to both outcomes (S5 Table). When evaluated in Cox regression
models, with stepwise selection algorithm, high values of VEGF-C were associated with both
overall and disease-free survival with a statically significant HR of 2.76 (95% CI: 1.27, 5.98;
p = 0.01) and 2.82 (95%CI: 1.62, 4.91; p<0.001) respectively (Fig 4, S5 Table).
Discussion
Finding new markers to assess prognosis of melanoma without the necessity to perform a sur-
gical interventions is an important goal in melanoma research. In this study on patients with
melanoma we assessed for the first time, the correlation between clinical follow up and prog-
nosis, and the expression of VEGF family and their receptors using a ngTMA full-automated
analysis.
Malignant melanoma has been shown as an angiogenic tumor type because the vessel for-
mation is an important step in disease progression from atypical melanocytes. However, the
exact role of angiogenesis, regulation of tumor lymphangiogenesis, role of VEGFs and their
receptors in the patients‘survival has remained unclear. In addition, despite different studies,
no antiangiogenic therapy has yet been approved for MM. [13]
Fig 2. Box and whisker plots of scores by patient’s diagnosis.
https://doi.org/10.1371/journal.pone.0207019.g002
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Among the angiogenic growth factors, the VEGF family and their corresponding receptors
play a crucial role regulating the angiogenic and lymphangiogenic processes. [11, 39] VEGF-A,
VEGF-B, VEGF-C, and VEGF-D have been identified as the most important members of the
family to date. [11, 40, 41] The result of current study declared, that VEGF-C and VEGF-R2
and VEGF-R3 seem to form separate sub-clusters, which might explain their interactions.
Recent studies showed that, VEGF-A and VEGF-D exert their action through VEGFR-1 and
VEGFR-2. While VEGF-B performs its action through VEGFR-1, and VEGF-C exerts its
action through VEGFR-2 and VEGFR-3. [11, 40, 41]
Whereas VEGF-A is best known for its angiogenetic ability in embryogenesis and patholog-
ical conditions, [42] VEGF-B is important for the conservation and survival of pathologically
formed blood vessels and in stressed conditions. [42, 43]
Increasing evidence show a specific role of VEGF-C and VEGF-R-3 in tumor lymphangio-
genesis and lymphatic metastasis in multiple solid tumor types. [44–47] VEGFR-3 can be
found on the endothelium of lymphatic vessels and some angiogenic tumor blood vessels. [48]
Fig 3. Dendrogram resulting from hierachical clustering analysis and presenting different clusters of correlated scores.
https://doi.org/10.1371/journal.pone.0207019.g003
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Thus, this receptor is indispensable for both angiogenesis and lymphangiogenesis. [49] Recent
experimental and clinical studies have implicated a positive association between VEGF-C
expression, peritumoral lymphangiogenesis, and metastasis of malignant cells. [44, 50] It has
been revealed that VEGF-C leads to an enlargement of peritumoral lymphatic vessels and
increasing lymph flow, which facilitates the dissemination rate to lymph nodes and lymphatic
intravasation. [44, 50] VEGF-C also contributes to tumor cell chemotaxis, which assists
tumoral spread. [44, 45, 50] A positive correlation between the expression of VEGF-C and the
extent of lymphatic metastasis has been found in breast, [17, 45] colorectal, [19] gastric, [25]
thyroid, [22, 23] lung, [20, 45] and prostate [51] cancers. Like other malignancies, in the cur-
rent study for the first time, significantly higher VEGF-C expression was detected in the meta-
static melanomas. In similar studies VEGF-C expression was found significantly increased in
metastatic melanoma compared to non-metastatic melanoma. [52–54] It has been also shown
in the current study, that the low values of VEGF-C were associated with better disease-free
and overall survival.
In the same way for VEGF-C, VEGF-D was found to be involved in lymphatic hyperplasia
and metastatic spread to lymph nodes by activating VEGFR-2 and VEGFR-3. [44–47, 55, 56]
VEGF-D overexpression has been also shown to lead tumor progression, enhanced metastasis
and reduced survival, [57–59] as well as poorly differentiated histology and increased invasive-
ness. [60, 61] We have also detected significantly higher VEGFR-2 expression in the metastatic
melanomas.
Table 2. Demographics and clinical characteristics of patients with a diagnosis of MM or metastasis, by kind of diagnosis and overall.
MM = 86 Metastasis = 51 Total = 137 P��
N�,% N�,% N�,%
Sex F 36,42.4% 18,36.0% 54,40.0% 0.467
M 49,57.6% 32,64.0% 81,60.0%
Age (yrs) Mean (SD) 60.6(16.0) 65.2(15.1) 62.3(15.8) 0.091
< 50 22,25.6% 8,16.0% 30,22.1%
50–64 28,32.6% 11,22.0% 39,28.7%
65+ 36,41.9% 31,62.0% 67,49.3%
Tumour type NM 16,18.6% 23,47.9% 39,29.1% <0.001
SMM 53,61.6% 10,20.8% 63,47.0%
Other 17,19.8% 15,31.2% 32,23.9%
Tumour location Head and Neck 12,14.3% 17,34.7% 29,21.8% 0.004
Trunk 44,52.4% 11,22.4% 55,41.4%
Upper Extremity 11,13.1% 7,14.3% 18,13.5%
Lower Extremity 17,20.2% 14,28.6% 31,23.3%
Ulceration No 72,86.7% 17,47.2% 89,74.8% <0.001
Yes 11,13.3% 19,52.8% 30,25.2%
Thickness (mm) Mean, SD 1.4(1.5) 4.2(3.6) 2.3(2.7) <0.001
Thin 48,55.8% 3,7.0% 51,39.5%
Intermediate 34,39.5% 25,58.1% 59,45.7%
Thick 4,4.7% 15,34.9% 19,14.7%
SLNB findings Negative 40,81.6% 16,61.5% 56,74.7% 0.057
Positive 9,18.4% 10,38.5% 19,25.3%
NM: Nodular melanoma, MM: malignant melanoma, P: p-value, SD: standard deviation, SLN: Sentinel lymph node biopsy, SSM: Superficial spreading melanoma
� Numbers may not add up to the total due to missing data
�� Pearson’s X2 test or Mann-Whitney U test were used for categorical and continuous variables respectively
https://doi.org/10.1371/journal.pone.0207019.t002
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The current study is not without limitations. The donor blocks must be made using stan-
dard molds and cassettes as the instrument cannot adjust itself to various sizes. Additionally,
donor blocks must exceed the minimal height (4 mm) to achieve optimal drilling. In some
cases, this requires re-embedding of tissues. [32] Furthermore, sometimes the tissue cores do
not attach properly to the slides and detach during the staining processes. However, ngTMA is
a substantial improvement over conventional tissue microarraying techniques. It incorporates
expertise in histology and ngTMA design with the flexibility of digital pathology and the preci-
sion of digital annotations with the speed and reliability of automated ngTMA construction.
[32] In this method immunohistochemistry staining is performed only for one slide instead of
hundred slides in the same condition with lower amount of needed antibodies and staining
materials. This technique enables also image analysis for evaluation of protein and molecular
biomarkers in a non-biased, fast, precise, fully-automated and quantitative manner.
In conclusion, since prognosis is a very crucial to prepare an individual therapy plan,
imprecisions in guidelines lead to both over- und under-treatment. Despite extensive investi-
gations to date, there is still a need for a non-invasive applicable prognostic marker to precisely
identify the management strategy and follow the treatment efficacy of the high-risk malignant
Table 3. Factors associated to study scores and selected by multivariate analysis, in patients with a diagnosis of MM.
VEGFA VEGFB VEGFC VEGFD VEGFR1 VEGFR2 VEGFR3 P��
Diff.
(95% CI)
P�
(Cr P^)
Diff.
(95% CI)
P�
(Cr P^)
Diff.
(95% CI)
P�
(Cr P^)
Diff.
(95% CI)
P�
(Cr P^)
Diff.
(95% CI)
P�
(Cr P^)
Diff.
(95% CI)
P�
(Cr P^)
Diff.
(95% CI)
P�
(Cr P^)
Tumour
type
NM Ref. 0.563
(0.046)
Ref. 0.322
(0.043)
Ref. 0.003
(0.021)
Ref. 0.066
(0.036)
Ref. 0.571
(0.050)
Ref. 0.130
(0.039)
Ref. 0.023
(0.025)
0.001
SSM 0.17
(-0.63,
0.98)
0.666
(0.039)
-0.01
(-0.85,
0.83)
0.980
(0.050)
-4.41
(-6.91,
-1.90)
0.001
(0.007)
-1.99
(-3.69,
-.29)
0.022
(0.020)
-0.07
(-0.74,
.59)
0.827
(0.045)
-3.47
(-6.96,
.02)
0.052
(0.023)
-4.78
(-8.34,
-1.22)
0.009
(0.014)
Other 0.48
(-0.45,
1.40)
0.310
(0.034)
0.54
(-0.43,
1.51)
0.272
(0.030)
-4.19
(-7.10,
-1.29)
0.005
(0.013)
-1.85
(-3.82,
0.12)
0.065
(0.025)
0.24
(-0.53,
1.01)
0.535
(0.036)
-3.50
(-7.54,
0.54)
0.089
(0.027)
-5.03
(-9.15,
-.91)
0.017
(0.018)
Thickness Thin Ref. 0.028
(0.029)
Ref. 0.002
(0.018)
Ref. <0.001
(0.004)
Ref. <0.001
(0.007)
Ref. 0.052
(0.032)
Ref. 0.001
(0.011)
Ref. 0.001
(0.014)
0.03
Intermediate 0.78
(0.16,
1.40)
0.014
(0.016)
1.14
(0.50,
1.79)
0.001
(0.009)
3.53
(1.59,
5.46)
0.001
(0.011)
2.58
(1.27,
3.89)
<0.001
(0.002)
0.58
(0.07,
1.10)
0.026
(0.021)
5.06
(2.36,
7.76)
<0.001
(0.004)
5.15
(2.40,
7.90)
<0.001
(0.005)
Thick 0.27
(-1.65,
1.10)
0.691
(0.041)
0.03
(-1.40,
1.47)
0.962
(0.046)
-2.27
(-6.56,
2.03)
0.297
(0.032)
-1.86
(-4.77,
1.05)
0.207
(0.029)
-0.21
(-1.35,
0.93)
0.713
(0.043)
-.13
(-6.11,
5.84)
0.964
(0.048)
-1.45
(-7.54,
4.65)
0.638
(0.038)
Primary
tumour
location
Head and
Neck
Ref. 0.04
(0.029)
Ref. 0.007
(0.014)
Ref. 0.1
(0.036)
Ref. <0.001
(0.007)
Ref. 0.10
(0.043)
Ref. 0.026
(0.021)
Ref. 0.18
(0.05)
0.005
Trunk 0.32
(-0.31,
0.95)
0.315
(0.029)
0.44
(-.43,
1.30)
0.315
(0.031)
2.30
(-1.03,
5.64)
0.171
(0.024)
2.12
(.63,
3.62)
0.006
(0.007)
0.08
(-0.35,
0.52)
0.701
(0.04)
6.36
(1.37,
11.35)
0.014
(0.014)
3.22
(-1.67,
8.11)
0.192
(0.026)
Upper Ext. .001
(-0.73,
0.73)
0.998
(0.05)
0.02
(-0.98,
1.03)
0.966
(0.045)
1.13
(-2.74,
5.00)
0.558
(0.038)
-.02
(-1.76,
1.72)
0.982
(0.048)
0.05
(-0.45,
0.56)
0.837
(0.043)
2.47
(-3.32,
8.26)
0.394
(0.036)
2.75
(-2.92,
8.43)
0.333
(0.033)
Lower Ext. 0.81
(0.23,
1.40)
0.008
(0.01)
1.39
(0.58,
2.19)
0.001
(0.005)
3.88
(.77,
6.99)
0.016
(0.017)
3.17
(1.78,
4.57)
<0.001
(0.002)
0.48
(0.08,
0.89)
0.021
(0.019)
6.33
(1.67,
10.98)
0.009
(0.012)
5.02
(0.46,
9.58)
0.032
(0.021)
CI: confidence interval, NM: Nodular melanoma, MM: malignant melanoma, SSM: Superficial spreading melanoma, P: p-value
� P-values in italics are single p-values from multivariate GLM analysis. Other p-values test the differences against a reference category for each score.
�� Overall p-value.
^ Benjamini–Hochberg critical values for multiple comparisons with a false discovery rate of 0.05. A first set of tests was performed on the overall difference for each
score; then a second sub-set of tests was done on the specific differences within each score. Results must be considered statistically significant (boldfaced) only when
their p-values are lower than the corresponding critical values (Cr. P).
https://doi.org/10.1371/journal.pone.0207019.t003
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melanoma. The result of the current study declared that VEGF-C and VEGF-R2 expression as
well as their extent might represent new prognostic markers in malignant melanoma. How-
ever, further prospective studies are warranted to test the accuracy and efficacy of these factors
as new prognostic markers and possibly new individualized targets for antiangiogenic therapy
in malignant melanoma. [62–64]
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